1. Home
  2. KXIN vs JAGX Comparison

KXIN vs JAGX Comparison

Compare KXIN & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KXIN

Kaixin Auto Holdings

HOLD

Current Price

$4.61

Market Cap

4.7M

ML Signal

HOLD

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$1.19

Market Cap

3.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KXIN
JAGX
Founded
2015
2013
Country
China
United States
Employees
N/A
N/A
Industry
Retail-Auto Dealers and Gas Stations
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7M
3.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
KXIN
JAGX
Price
$4.61
$1.19
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$60.00
AVG Volume (30 Days)
1.5M
380.3K
Earning Date
01-01-0001
11-17-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$95,000.00
$11,785,000.00
Revenue This Year
N/A
$22.41
Revenue Next Year
N/A
$30.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
12.45
52 Week Low
$2.94
$1.00
52 Week High
$75.00
$33.25

Technical Indicators

Market Signals
Indicator
KXIN
JAGX
Relative Strength Index (RSI) 64.63 41.39
Support Level $3.32 $1.05
Resistance Level $5.40 $1.36
Average True Range (ATR) 0.85 0.16
MACD 0.14 0.04
Stochastic Oscillator 78.25 38.00

Price Performance

Historical Comparison
KXIN
JAGX

About KXIN Kaixin Auto Holdings

Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Share on Social Networks: